Showing results (421-430 of 430) with videos related to

Sort By:
Pageof 43
You have reached the last page of results.This site can display upto 430 results.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Current Biology : CB|June 25, 2011
Arabidopsis PLETHORA transcription factors control phyllotaxisKalika Prasad, Stephen P Grigg, Michalis Barkoulas, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Leukemia|October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsDavid M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
Bone & Joint Open|July 6, 2026
The Reconstructive Pelvic Anatomy classification system : a valid and reliable classification system for pelvic reconstructionWilliam J J Collins, Daniel Franks, Ian A Harris, et al.
Transplantation and Cellular Therapy|June 6, 2026
Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell TransplantationNermen Tawfik, Ashleigh P Scott, Catelyn Cashion, et al.
British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Pageof 43